Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash from Operations: 2020-2024

Historic Cash from Operations for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to -$55.0 million.

  • Immuneering's Cash from Operations fell 23.23% to -$14.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$55.0 million, marking a year-over-year decrease of 12.32%. This contributed to the annual value of -$55.0 million for FY2024, which is 12.32% down from last year.
  • As of FY2024, Immuneering's Cash from Operations stood at -$55.0 million, which was down 12.32% from -$49.0 million recorded in FY2023.
  • Over the past 5 years, Immuneering's Cash from Operations peaked at -$14.6 million during FY2020, and registered a low of -$55.0 million during FY2024.
  • Over the past 3 years, Immuneering's median Cash from Operations value was -$49.0 million (recorded in 2023), while the average stood at -$49.4 million.
  • Data for Immuneering's Cash from Operations shows a maximum YoY crashed of 111.01% (in 2021) over the last 5 years.
  • Over the past 5 years, Immuneering's Cash from Operations (Yearly) stood at -$14.6 million in 2020, then plummeted by 111.01% to -$30.9 million in 2021, then tumbled by 42.95% to -$44.1 million in 2022, then declined by 11.04% to -$49.0 million in 2023, then fell by 12.32% to -$55.0 million in 2024.